このページの翻訳は実験的なもので、現在開発中です。お待ちしております

China Medical System Holdings 将来の成長

Future 基準チェック /46

China Medical System Holdings利益と収益がそれぞれ年間22.7%と15.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.8% 23%なると予測されています。

主要情報

21.4%

収益成長率

21.9%

EPS成長率

Pharmaceuticals 収益成長	9.2%
収益成長率	14.7%
将来の株主資本利益率	15.4%
アナリストカバレッジ	Good
最終更新日	20 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

SHSC:867 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10,409	2,589	2,761	2,675	8
12/31/2025	8,938	2,039	2,036	1,938	10
12/31/2024	7,836	1,766	1,986	1,886	10
6/30/2024	7,014	1,390	1,235	1,885	N/A
3/31/2024	7,514	1,896	1,717	2,194	N/A
12/31/2023	8,013	2,401	2,200	2,503	N/A
9/30/2023	8,663	2,891	2,615	3,047	N/A
6/30/2023	9,313	3,381	3,031	3,592	N/A
3/31/2023	9,232	3,320	3,029	3,573	N/A
12/31/2022	9,150	3,259	3,028	3,553	N/A
9/30/2022	9,046	3,224	2,698	3,032	N/A
6/30/2022	8,942	3,189	2,367	2,511	N/A
3/31/2022	8,640	3,103	2,338	2,502	N/A
12/31/2021	8,337	3,017	2,309	2,494	N/A
9/30/2021	8,009	2,948	2,373	2,591	N/A
6/30/2021	7,681	2,878	2,437	2,688	N/A
3/31/2021	7,313	2,704	2,394	2,690	N/A
12/31/2020	6,946	2,530	2,351	2,692	N/A
9/30/2020	6,582	2,300	2,286	2,661	N/A
6/30/2020	6,217	2,070	2,222	2,631	N/A
3/31/2020	6,145	2,015	2,218	2,593	N/A
12/31/2019	6,074	1,961	2,215	2,555	N/A
9/30/2019	5,908	2,011	2,087	2,344	N/A
6/30/2019	5,743	2,062	1,960	2,132	N/A
3/31/2019	5,588	1,956	1,829	1,943	N/A
12/31/2018	5,433	1,850	1,698	1,755	N/A
9/30/2018	5,375	1,839	1,813	1,875	N/A
6/30/2018	5,317	1,827	1,928	1,996	N/A
3/31/2018	5,333	1,751	N/A	2,034	N/A
12/31/2017	5,349	1,675	N/A	2,072	N/A
9/30/2017	5,379	1,601	N/A	1,876	N/A
6/30/2017	5,410	1,527	N/A	1,679	N/A
3/31/2017	5,155	1,452	N/A	1,421	N/A
12/31/2016	4,901	1,376	N/A	1,162	N/A
9/30/2016	4,477	1,265	N/A	1,134	N/A
6/30/2016	4,054	1,155	N/A	1,105	N/A
3/31/2016	3,804	1,075	N/A	860	N/A
12/31/2015	3,553	996	N/A	615	N/A
9/30/2015	3,404	1,062	N/A	528	N/A
6/30/2015	3,255	1,128	N/A	441	N/A
3/31/2015	3,100	1,087	N/A	642	N/A
12/31/2014	2,945	1,046	N/A	843	N/A
9/30/2014	2,760	890	N/A	689	N/A
6/30/2014	2,575	734	N/A	535	N/A
3/31/2014	2,412	685	N/A	435	N/A
12/31/2013	2,249	636	N/A	335	N/A
9/30/2013	2,081	603	N/A	417	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 867の予測収益成長率 (年間6.8% ) は貯蓄率 ( 2.2% ) を上回っています。

収益対市場: 867の収益 ( 21.9% ) はHong Kong市場 ( 11% ) よりも速いペースで成長すると予測されています。

高成長収益: 867の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 867の収益 ( 10.4% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 867の収益 ( 10.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 867の自己資本利益率は、3年後には低くなると予測されています ( 15.8 %)。

China Medical System Holdings 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Recent updates

China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Founder recently bought HK$3.6m worth of stock

First half dividend of HK$0.16 announced

First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023)

China Medical System Holdings Limited Announces Re-Designation of Directors

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024

China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection

Now 20% undervalued after recent price drop

Founder recently bought HK$6.8m worth of stock

Now 20% undervalued after recent price drop

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023

Now 21% undervalued after recent price drop

China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 40%

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

Final dividend of HK$0.086 announced

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Now 38% undervalued after recent price drop

Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022)

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China

Upcoming dividend of HK$0.34 per share at 5.1% yield

First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023

China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray

National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI

Upcoming dividend of HK$0.27 per share at 4.5% yield

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China

Investor sentiment improved over the past week

Upcoming dividend of HK$0.34 per share

First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022

China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.28 per share

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022

China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China

Independent Non-Executive Director Chi Keung Wu has left the company

China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria

Upcoming dividend of HK$0.32 per share

First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020)

National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe

China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China

China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019)

China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021

Full year 2020 earnings released

Investor sentiment improved over the past week

China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment deteriorated over the past week

New 90-day high: HK$13.58

China Medical System Holdings Limited (SEHK:867) acquired Luqa Ventures Co., Ltd. from third party sellers.

Investor sentiment improved over the past week

China Medical System Holdings Limited Announces Desidustat Tablets Being Granted an Approval for Drug Clinical Trial

New 90-day high: HK$10.38

New 90-day high: HK$9.04

Founder recently bought HK$23m worth of stock

China Medical System Holdings Limited through its Wholly-Owned Subsidiary Signs License, Collaboration and Distribution Agreement with Cosmo Technologies Ltd

New 90-day low: HK$7.92

New 90-day low: HK$8.47